Dechra Acquires Exclusive License from Hassinger Biomedical for Equine ProVet APC™

Tuesday, September 28, 2021

Dechra Veterinary Products is pleased to announce the acquisition of the veterinary marketing and distribution rights to the ProVet APC™ (Autologous Platelet Concentrate) and ProVet BMC™ (Bone Marrow Concentrate) systems from Hassinger Biomedical. These two patented medical devices concentrate platelets or bone marrow in 90 seconds with a processing time of 2.5 minutes from start to finish.

The ProVet APC system is a revolutionary device and is arguably the fastest and most transportable platelet concentrator available to the veterinary industry at less than 3 pounds total weight. Some of the system features include the ability to isolate approximately 90% of available platelets and growth factors, delivering the highest level of reproducibility with a low 3.5% coefficient of variance and a 97% reduction in red blood cell numbers.

The proprietary technology found within ProVet APC consistently delivers 6 to 8mls of 7.8 times high concentration of platelet rich plasma and a healing concentrate derived from 54mls of whole blood in the 60ml system.

Mike Eldred, President of Dechra North America stated, “The medical industry has long recognized that harnessing the growth factors found in platelets positively enhances healing results and reduces recovery time in soft tissue injuries. These two products will be great additions to our equine product line and further strengthen our market position in veterinary regenerative medicine”.

“ProVet APC has become the most highly sought-after regenerative system for equine athletes”, said Amy Hassinger, CEO Hassinger Biomedical. “We believe Dechra is specially poised, through their experience in the veterinary sector to meet the growing global demand by veterinarians and their clients for the ProVet APC and BMC Regenerative Therapy Systems.”

This addition of the Provet APC products to Dechra’s equine portfolio will complement our industry leading Orthokine® Vet irap joint therapy and provides veterinarians with a one stop partner for their regenerative medicine needs.

About Dechra

Dechra Veterinary Products, located in Overland Park, Kansas, is the U.S. sales and marketing division of Dechra Pharmaceuticals PLC, a UK listed company dedicated to the animal healthcare market. Dechra’s equine product line includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, Osteokine® (PRP), Equidone® (domperidone) Gel, the Vetivex® line of parenteral fluids, Phycox® EQ, and a comprehensive line of topical dermatologic products. The recent addition of Zimeta® (dipyrone injection) further expands Dechra’s equine offerings. Dechra Veterinary Products’ companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our companion animal brands include Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), Osurnia® (florfenicolterbinafine-betamethasone acetate), Mirataz® (mirtazapine transdermal ointment), and Phycox® joint health supplements, Porus® One as well as a comprehensive topical dermatologic line for veterinary use. For more information, please visit www.dechra-us.com or call (866) 933-2472.

For questions or further information, please contact Mike Eldred or Doug Hubert:

Mike Eldred, President, North American Operations, Dechra Veterinary Products, Mike.Eldred@Dechra.com

Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products, Doug.Hubert@Dechra.com